amoxicillin clavulanate potassium tablets 875 mg

drug

Before a new drug enters the market, the pharmaceutical company must submit a summary of product characteristics (SmPC) as part of marketing authorization. This should contain all relevant study data and information on the safe and effective use of the drug, preferably from randomized controlled trials (RCTs). Patient-reported outcomes (PROs) are also highly relevant here, as by means of these outcomes, patients themselves assess how a medical intervention affects symptoms or health-related quality of life, for example. These subjective endpoints are very important for the assessment of the benefits and harms of drugs: In order to reflect the patient perspective, the collection of data on PROs in clinical trials has therefore increased markedly in recent years.

In the early benefit assessment of drugs in Germany according to the Act on the Reform of the Market for Medicinal Products (AMNOG), after marketing authorization pharmaceutical companies must submit the complete evidence on a new drug in their dossiers. IQWiG’s subsequent dossier assessments explicitly consider PROs.

Source: Read Full Article